Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2023 Publisher: Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, Dublin, D15 T867
Azactam 1 g Powder for Solution for Injection or Infusion.
Azactam 2 g Powder for Solution for Injection or Infusion.
| Pharmaceutical Form |
|---|
|
Powder for solution for injection or infusion. |
Each vial contains 1 g aztreonam.
Each vial contains 2 g aztreonam.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Aztreonam |
Aztreonam exhibits activity in vitro against gram-negative aerobic pathogens, including P. aeruginosa. Aztreonam binds to penicillin-binding proteins of susceptible bacteria, which leads to inhibition of bacterial cell wall synthesis, followed by filamentation and cell lysis. |
| List of Excipients |
|---|
|
L-arginine 780 mg per g of aztreonam |
Type III clear molded glass vials, closed with silicone grey butyl rubber closure, and sealed with aluminium seal with flip off plastic button:
1 g glass vials: pack of 1 × 15 mL
2 g glass vials: pack of 1 × 15 mL
Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, Dublin, D15 T867
Azactam 1 g vial: PL 12038/0002
Azactam 2 g vial: PL 12038/0003
15th October 1986 / 22nd November 1991 / 13th August 1998
| Drug | Countries | |
|---|---|---|
| AZACTAM | Austria, Spain, Finland, France, Ireland, Japan, Malta, New Zealand, Singapore, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
